The Cooper Companies, Inc. (COO) key performance indicators and operating metrics (20 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| CooperSurgical Revenue | 358M | FY2026-Q2 |
| CooperVision Revenue | 723.5M | FY2026-Q2 |
| Diluted Earnings per Share (Non-Generally Accepted Accounting Principles) | 1.21 USD_per_share | FY2026-Q2 |
| Gross Margin (Non-Generally Accepted Accounting Principles) | 68.00 percent | FY2026-Q2 |
| Operating Margin (Non-Generally Accepted Accounting Principles) | 27.00 percent | FY2026-Q2 |
| Free Cash Flow | 96.4M | FY2026-Q2 |
| CooperSurgical Fertility Sales | 143.8M | FY2026-Q2 |
| CooperSurgical Office and Surgery Sales | 214.2M | FY2026-Q2 |
| Cooper Vision operating income | 215.6M | FY2026-Q2 |
| Cooper Surgical operating income | 26.8M | FY2026-Q1 |
| Gross Margin (Generally Accepted Accounting Principles) | 68.00 percent | FY2026-Q2 |
| CooperVision Toric and Multifocal Revenue | 364.9M | FY2026-Q2 |
| Coopervision · Sphere Other revenue | 358.6M | FY2026-Q2 |
| Operating Margin (Generally Accepted Accounting Principles) | -3.00 percent | FY2026-Q2 |
Back to COO overview · COO earnings · COO holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.